Boundless Bio

Boundless Bio is a clinical-stage, next-generation precision oncology company based in San Diego, California, dedicated to developing novel therapies for patients with intractable oncogene-amplified cancers. The company describes itself as the first company dedicated to treating oncogene-amplified cancers and as a leader in the field of extrachromosomal DNA (ecDNA). Its scientific premise is that ecDNA — circular DNA structures rarely seen in healthy cells but found in the cancer cells of over 17% of patients with solid tumors — is a root cause of oncogene amplifications and a therapeutically actionable vulnerability of cancer cells. According to its official website, Boundless Bio is advancing a pipeline of ecDNA-directed therapies (ecDTx), a new vertical of cancer therapeutics. The company frames the medical need in stark terms: more than 25% of all cancers have oncogene amplifications, and more than 5 million newly diagnosed cancers each year around the world harbor oncogene amplifications. It notes that while targeted therapies and immunotherapies have advanced treatment for cancers driven by oncogene mutations or fusions, those approaches have proven largely ineffective in patients whose cancers are driven by oncogene amplification, leaving poor prognosis and survival for the vast majority of these patients. Boundless Bio positions itself around a comprehensive approach to understanding how cancer cells utilize ecDNA, aiming to identify and therapeutically exploit unique vulnerabilities of ecDNA in cancer cells. The company is led by a team it describes as experienced precision oncology leaders with deep scientific, clinical, diagnostic, and business expertise, supported by a board of directors and a scientific and clinical advisory board that includes academic researchers in cancer biology, chemical biology, and computational science. As a clinical-stage company, Boundless Bio's activities center on drug discovery and development rather than marketed products. Its public identity emphasizes boldness, creativity, and collaboration, captured in the internal motto "We are unbound by convention, bound to save lives." The company is headquartered in San Diego, United States.

Boundless Bio is a clinical-stage precision oncology company headquartered in San Diego, California. Publicly available information about the company is centered on its scientific platform and leadership rather than a long corporate history. The company was founded to pursue a then-novel therapeutic hypothesis: that extrachromosomal DNA (ecDNA) — circular DNA elements that are rarely found in healthy cells but appear in the cancer cells of a substantial share of solid-tumor patients — is a root cause of oncogene amplification and therefore a targetable vulnerability. According to its official website, Boundless Bio describes itself as the first company dedicated to treating oncogene-amplified cancers and as a leader in the ecDNA field. It has built its identity around ecDNA-directed therapies (ecDTx), which it characterizes as an entirely new vertical of cancer therapeutics. The company's rationale rests on the observation that more than 25% of all cancers carry oncogene amplifications, and that more than 5 million newly diagnosed cancers each year worldwide harbor such amplifications. While targeted therapies and immunotherapies have improved outcomes for cancers driven by oncogene mutations or fusions, Boundless Bio states that these approaches have proven largely ineffective for cancers driven by oncogene amplification, leaving a large unmet need. Boundless Bio's approach combines biology, diagnostics, and computational analysis to understand how cancer cells utilize ecDNA, with the goal of identifying and exploiting ecDNA-specific vulnerabilities. The company is led by a team it describes as experienced precision oncology leaders with scientific, clinical, diagnostic, and business expertise. Its board of directors includes James "Jamie" Christensen, Ph.D.; Nancy Whiting, Pharm.D.; Jennifer Lew; and Jonathan Lim, M.D., who serves as Chairman and Co-Founder. Its scientific and clinical advisory board includes George Demetri, M.D., of Harvard Medical School and Dana-Farber Cancer Institute; James L. Freddo, M.D.; Vineet Bafna, Ph.D., of UC San Diego; Ben Cravatt, Ph.D., of The Scripps Research Institute; and Paul Mischel, M.D., of Stanford University, who chairs the scientific advisory board. As of the available evidence, Boundless Bio remains an active, clinical-stage company focused on advancing its ecDTx pipeline. The company's public messaging emphasizes boldness, creativity, and collaboration, summarized in the phrase "We are unbound by convention, bound to save lives." Detailed dated milestones such as founding year, financing rounds, and clinical trial starts are not provided in the supplied evidence and are therefore not asserted here.

Clinical-stage precision oncology company and self-described leader in ecDNA-directed therapies for oncogene-amplified cancers.

• ecDNA-directed therapies (ecDTx)

  A pipeline of next-generation cancer medicines designed to target extrachromosomal DNA (ecDNA) vulnerabilities in oncogene-amplified cancers.

1. 1Boundless Bioboundlessbio.com
2. 2Who We Are - Boundless Bioboundlessbio.com
3. 3Boundless Bio (United States) - Wikidatawikidata.org